Incidence, clinical features, risk factors, and outcomes of Intraocular inflammation following Brolucizumab in Indian eyes – A multicentric study
Purpose: To report the incidence, clinical features, potential risk factors, and outcomes of intraocular inflammation (IOI) following brolucizumab in Indian eyes. Methods: All consecutive patients diagnosed with brolucizumab-induced IOI from 10 centers in eastern India between October 2020 and Apr...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2023-01-01
|
| Series: | Indian Journal of Ophthalmology |
| Subjects: | |
| Online Access: | http://www.ijo.in/article.asp?issn=0301-4738;year=2023;volume=71;issue=5;spage=1979;epage=1985;aulast=Chakraborty |
| _version_ | 1797775122870829056 |
|---|---|
| author | Debdulal Chakraborty Soumen Mondal Sabyasachi Sengupta Zahir Abbas Khushboo Chandra Subhendu Boral Aniruddha Maiti Sangeeta Roy Angshuman Mukherjee Arnab Das Somnath Chakraborty Pinaki Nag |
| author_facet | Debdulal Chakraborty Soumen Mondal Sabyasachi Sengupta Zahir Abbas Khushboo Chandra Subhendu Boral Aniruddha Maiti Sangeeta Roy Angshuman Mukherjee Arnab Das Somnath Chakraborty Pinaki Nag |
| author_sort | Debdulal Chakraborty |
| collection | DOAJ |
| description | Purpose: To report the incidence, clinical features, potential risk factors, and outcomes of intraocular inflammation (IOI) following brolucizumab in Indian eyes. Methods: All consecutive patients diagnosed with brolucizumab-induced IOI from 10 centers in eastern India between October 2020 and April 2022 were included. Results: Of 758 injections given during the study period across centers, 13 IOI events (1.7%) were recorded attributable to brolucizumab. The IOI occurred after the first dose in two eyes (15%) (median 45 days after brolucizumab), second dose in six eyes (46%) (median = 8.5 days), and third dose (39%) in the remaining five eyes (median 7 days). Reinjections of brolucizumab were administered at a median interval of 6 weeks (interquartile range = 4–10 weeks) in the 11 eyes, where IOI occurred after the second or third dose. Eyes that experienced IOI after the third dose had received a significantly greater number of previous antivascular endothelial growth factor injections (median = 8) compared to those who developed it after the first or second dose (median = 4) (P = 0.001). Anterior chamber cells were seen in almost all eyes (n = 11, 85%), while peripheral retinal hemorrhages were seen in two eyes, and one eye showed branch artery occlusion. Two-thirds of patients (n = 8, 62%) recovered with a combination of topical and oral steroids, while remaining recovered with topical steroids alone. Irreversible visual loss was not seen in any eye, and median vision recovered to pre-IOI levels by 3 months' time point. Conclusion: Brolucizumab-induced IOI was relatively rare, occurring in 1.7% of eyes, was more common after the second or third injection, especially in those who required frequent reinjections every 6 weeks, and occurred earlier with increasing number of previous brolucizumab injections. Continued surveillance is necessary even after repeated doses of brolucizumab. |
| first_indexed | 2024-03-12T22:31:08Z |
| format | Article |
| id | doaj.art-fbd5b3ab0a594d63b0b945ad2557a58e |
| institution | Directory Open Access Journal |
| issn | 0301-4738 1998-3689 |
| language | English |
| last_indexed | 2024-03-12T22:31:08Z |
| publishDate | 2023-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Indian Journal of Ophthalmology |
| spelling | doaj.art-fbd5b3ab0a594d63b0b945ad2557a58e2023-07-21T15:14:09ZengWolters Kluwer Medknow PublicationsIndian Journal of Ophthalmology0301-47381998-36892023-01-017151979198510.4103/IJO.IJO_2688_22Incidence, clinical features, risk factors, and outcomes of Intraocular inflammation following Brolucizumab in Indian eyes – A multicentric studyDebdulal ChakrabortySoumen MondalSabyasachi SenguptaZahir AbbasKhushboo ChandraSubhendu BoralAniruddha MaitiSangeeta RoyAngshuman MukherjeeArnab DasSomnath ChakrabortyPinaki NagPurpose: To report the incidence, clinical features, potential risk factors, and outcomes of intraocular inflammation (IOI) following brolucizumab in Indian eyes. Methods: All consecutive patients diagnosed with brolucizumab-induced IOI from 10 centers in eastern India between October 2020 and April 2022 were included. Results: Of 758 injections given during the study period across centers, 13 IOI events (1.7%) were recorded attributable to brolucizumab. The IOI occurred after the first dose in two eyes (15%) (median 45 days after brolucizumab), second dose in six eyes (46%) (median = 8.5 days), and third dose (39%) in the remaining five eyes (median 7 days). Reinjections of brolucizumab were administered at a median interval of 6 weeks (interquartile range = 4–10 weeks) in the 11 eyes, where IOI occurred after the second or third dose. Eyes that experienced IOI after the third dose had received a significantly greater number of previous antivascular endothelial growth factor injections (median = 8) compared to those who developed it after the first or second dose (median = 4) (P = 0.001). Anterior chamber cells were seen in almost all eyes (n = 11, 85%), while peripheral retinal hemorrhages were seen in two eyes, and one eye showed branch artery occlusion. Two-thirds of patients (n = 8, 62%) recovered with a combination of topical and oral steroids, while remaining recovered with topical steroids alone. Irreversible visual loss was not seen in any eye, and median vision recovered to pre-IOI levels by 3 months' time point. Conclusion: Brolucizumab-induced IOI was relatively rare, occurring in 1.7% of eyes, was more common after the second or third injection, especially in those who required frequent reinjections every 6 weeks, and occurred earlier with increasing number of previous brolucizumab injections. Continued surveillance is necessary even after repeated doses of brolucizumab.http://www.ijo.in/article.asp?issn=0301-4738;year=2023;volume=71;issue=5;spage=1979;epage=1985;aulast=Chakrabortyafliberceptbrolucizumabintraocular inflammation following brolucizumabnamd |
| spellingShingle | Debdulal Chakraborty Soumen Mondal Sabyasachi Sengupta Zahir Abbas Khushboo Chandra Subhendu Boral Aniruddha Maiti Sangeeta Roy Angshuman Mukherjee Arnab Das Somnath Chakraborty Pinaki Nag Incidence, clinical features, risk factors, and outcomes of Intraocular inflammation following Brolucizumab in Indian eyes – A multicentric study Indian Journal of Ophthalmology aflibercept brolucizumab intraocular inflammation following brolucizumab namd |
| title | Incidence, clinical features, risk factors, and outcomes of Intraocular inflammation following Brolucizumab in Indian eyes – A multicentric study |
| title_full | Incidence, clinical features, risk factors, and outcomes of Intraocular inflammation following Brolucizumab in Indian eyes – A multicentric study |
| title_fullStr | Incidence, clinical features, risk factors, and outcomes of Intraocular inflammation following Brolucizumab in Indian eyes – A multicentric study |
| title_full_unstemmed | Incidence, clinical features, risk factors, and outcomes of Intraocular inflammation following Brolucizumab in Indian eyes – A multicentric study |
| title_short | Incidence, clinical features, risk factors, and outcomes of Intraocular inflammation following Brolucizumab in Indian eyes – A multicentric study |
| title_sort | incidence clinical features risk factors and outcomes of intraocular inflammation following brolucizumab in indian eyes a multicentric study |
| topic | aflibercept brolucizumab intraocular inflammation following brolucizumab namd |
| url | http://www.ijo.in/article.asp?issn=0301-4738;year=2023;volume=71;issue=5;spage=1979;epage=1985;aulast=Chakraborty |
| work_keys_str_mv | AT debdulalchakraborty incidenceclinicalfeaturesriskfactorsandoutcomesofintraocularinflammationfollowingbrolucizumabinindianeyesamulticentricstudy AT soumenmondal incidenceclinicalfeaturesriskfactorsandoutcomesofintraocularinflammationfollowingbrolucizumabinindianeyesamulticentricstudy AT sabyasachisengupta incidenceclinicalfeaturesriskfactorsandoutcomesofintraocularinflammationfollowingbrolucizumabinindianeyesamulticentricstudy AT zahirabbas incidenceclinicalfeaturesriskfactorsandoutcomesofintraocularinflammationfollowingbrolucizumabinindianeyesamulticentricstudy AT khushboochandra incidenceclinicalfeaturesriskfactorsandoutcomesofintraocularinflammationfollowingbrolucizumabinindianeyesamulticentricstudy AT subhenduboral incidenceclinicalfeaturesriskfactorsandoutcomesofintraocularinflammationfollowingbrolucizumabinindianeyesamulticentricstudy AT aniruddhamaiti incidenceclinicalfeaturesriskfactorsandoutcomesofintraocularinflammationfollowingbrolucizumabinindianeyesamulticentricstudy AT sangeetaroy incidenceclinicalfeaturesriskfactorsandoutcomesofintraocularinflammationfollowingbrolucizumabinindianeyesamulticentricstudy AT angshumanmukherjee incidenceclinicalfeaturesriskfactorsandoutcomesofintraocularinflammationfollowingbrolucizumabinindianeyesamulticentricstudy AT arnabdas incidenceclinicalfeaturesriskfactorsandoutcomesofintraocularinflammationfollowingbrolucizumabinindianeyesamulticentricstudy AT somnathchakraborty incidenceclinicalfeaturesriskfactorsandoutcomesofintraocularinflammationfollowingbrolucizumabinindianeyesamulticentricstudy AT pinakinag incidenceclinicalfeaturesriskfactorsandoutcomesofintraocularinflammationfollowingbrolucizumabinindianeyesamulticentricstudy |